3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
25
Myelodysplastic Syndromes
17
Lymphoma, Non-Hodgkin
16
Lymphoma
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, T-Cell, Peripheral
13
Multiple Myeloma
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Recurrence
10
Leukemia
10
Hodgkin Disease
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell
7
Lymphoma, Follicular
7
Hematologic Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Biphenotypic, Acute
6
Lymphoma, Extranodal NK-T-Cell
5
Leukemia, Myelomonocytic, Chronic
5
Primary Myelofibrosis
4
Myeloproliferative Disorders
4
Lymphoma, Mantle-Cell
4
Lymphoma, B-Cell
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Immunoblastic Lymphadenopathy
4
Prostatic Neoplasms
3
Neoplasms, Plasma Cell
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Large-Cell, Anaplastic
3
Interventions
midostaurin
3
avapritinib
2
ripretinib
1
nilotinib
1
ibrutinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
denileukin diftitox
1
auricularum
1
Ranitidine
1
Interviews as Topic
1
Ibuprofen
1
Diphenhydramine
1
Dexamethasone
1
Calcium Dobesilate
1
Brentuximab Vedotin
1
Azacitidine
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mastocytosis, Systemic
×
Azacitidine
×
Lymphoid
×
Clear all
NCT05609942
2025-04-10
AZURE
Blueprint Medicines Corporation
Phase 1
Terminated
9 enrolled